Research ArticleClinical Investigation
Metabolic Response of Non-Hodgkin's Lymphoma to 131I-Anti-B1 Radioimmunotherapy: Evaluation with FDG PET
Tatsuo Torizuka, Kenneth R. Zasadny, Paul V. Kison, Stephen G. Rommelfanger, Mark S. Kaminski and Richard L. Wahl
Journal of Nuclear Medicine June 2000, 41 (6) 999-1005;
Tatsuo Torizuka
Kenneth R. Zasadny
Paul V. Kison
Stephen G. Rommelfanger
Mark S. Kaminski
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Metabolic Response of Non-Hodgkin's Lymphoma to 131I-Anti-B1 Radioimmunotherapy: Evaluation with FDG PET
Tatsuo Torizuka, Kenneth R. Zasadny, Paul V. Kison, Stephen G. Rommelfanger, Mark S. Kaminski, Richard L. Wahl
Journal of Nuclear Medicine Jun 2000, 41 (6) 999-1005;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma
- 18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy
- Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography
- Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
- Early Response to Chemotherapy in Hypopharyngeal Cancer: Assessment with 11C-Methionine PET, Correlation with Morphologic Response, and Clinical Outcome
- 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
- A Tabulated Summary of the FDG PET Literature